(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 March 2024 (14.03.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/052684 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *C07K 16/28* (2006.01)
A61P 35/00 (2006.01) *C07D 471/04* (2006.01)

(21) International Application Number:
PCT/GB2023/052318

(22) International Filing Date:
08 September 2023 (08.09.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

22194959.7	09 September 2022 (09.09.2022)	EP
22194984.5	09 September 2022 (09.09.2022)	EP
2305546.0	14 April 2023 (14.04.2023)	GB
2305541.1	14 April 2023 (14.04.2023)	GB

(71) Applicants: **MYRICX PHARMA LIMITED** [GB/GB]; 125 Wood Street, London EC2V 7AW (GB). **IMPERIAL COLLEGE INNOVATIONS LIMITED** [GB/GB]; Level 1 Faculty Building, c/o Imperial College, Exhibition Road, London SW7 2AZ (GB).

(72) Inventors: **CARR, Robin**; c/o MyricX Pharma Limited, 125 Wood Street, London EC2V 7AW (GB). **SOLARI, Roberto**; c/o MyricX Pharma Limited, 125 Wood Street, London EC2V 7AW (GB). **TATE, Edward William**; c/o Imperial College Innovations Limited, Level 1 Faculty Building, c/o Imperial College, Exhibition Road, London SW7 2AZ (GB). **BELL, Andrew Simon**; c/o Imperial College Innovations Limited, Level 1 Faculty Building, c/o Imperial College, Exhibition Road, London SW7 2AZ (GB). **BONNERT, Roger**; c/o MMV Medicines for Malaria Venture, International Centre Cointrin, 20 Route de Pré-Bois, CH-1215 Cointrin Geneva (CH).

(74) Agent: **KINCH, Alison** et al.; Sagittarius IP, Marlow International, Parkway, Marlow, Buckinghamshire SL7 1YL (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2024/052684 A1

(54) Title: ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR AND ITS USE

(57) Abstract: The present invention relates to ADCs comprising a NMT inhibitor conjugated to an antibody via a linker, and related uses.